New Breast Imaging Technology Could Make Hormone Therapy Safer for Menopausal Women

This completed clinical trial investigated whether optical breast scanning technology could revolutionize hormone replacement therapy safety by identifying high-risk women early in treatment. Hormone replacement therapy presents a clinical dilemma: while it effectively treats menopause symptoms, it increases breast cancer risk in some women, leading to reduced prescribing rates.

The University Health Network study enrolled 14 postmenopausal women and monitored breast tissue changes using optical breast scanning during hormone replacement therapy. The observational trial ran from September 2011 to January 2015, tracking participants over several years to detect early tissue changes.

The researchers aimed to develop a decision-making tool that could identify women at risk for hormone therapy-induced breast cancer within months rather than years. This early detection capability could transform menopausal care by enabling personalized treatment decisions.

While specific results weren't detailed, the completed status suggests the technology showed promise for monitoring breast tissue changes. If validated in larger studies, this approach could allow doctors to confidently prescribe hormone therapy to more women while identifying and protecting those at higher risk.

For longevity and health optimization, this research represents progress toward personalized hormone therapy - a key component of healthy aging for women. Safe access to hormone replacement therapy could improve quality of life, bone health, and cardiovascular outcomes during the critical menopausal transition years.